Notice of Proposed Sale · 144
Amylyx Pharmaceuticals, Inc.
AMLXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Amylyx Pharmaceuticals, Inc.
- Issuer CIK
- 0001658551
- SEC file number
- 001-41199
- Phone
- (617)-682-0917
- Person for whose account securities are to be sold
- GINA MAZZARIELLO
- Relationships to issuer
- Officer
- Street
- 55 Cambridge Parkway,
- Street (continued)
- Suite 6W
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02142
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 30,000 | 536,400.00 | 111,186,317 | 07/09/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 03/31/2025 | Restricted Stock Units | Issuer | 30,000 | N | 03/31/2025 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 3/31/2025 through 9/30/2025.
Notice signature
- Notice date
- 07/09/2026
- Signed
- /s/ Gina Mazzariello
- Plan adoption dates
- 04/09/2026
Company context
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.